Phase 2, Phase 3 Recruiting Academic/Other
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Sponsor: NRG Oncology
NCT ID: NCT05174169
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Thomas Hospital — Fairhope, Alabama
- Mobile Infirmary Medical Center — Mobile, Alabama
+ 1020 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares total ablative therapy and usual systemic therapy to usual systemic therapy alone in treating patients with colorectal cancer that has spread to up to 4 body sites (limited metastatic). The usual approach for …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05673148
Locations: - Kingman Regional Medical Center — Kingman, Arizona
- Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- Tower Cancer Research Foundation — Beverly Hills, California
+ 182 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy …
Sponsor: Pfizer
NCT ID: NCT07222800
Locations: - Ironwood Cancer & Research Centers — Chandler, Arizona
- Ironwood Cancer & Research Centers — Gilbert, Arizona
- Ironwood Cancer & Research Centers — Glendale, Arizona
+ 178 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic color…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07221357
Locations: - Local Institution - 0428 — Tucson, Arizona
- Highlands Oncology Group — Springdale, Arkansas
- USC/Norris Comprehensive Cancer Center — Los Angeles, California
+ 43 more sites in the U.S.
Phase 3 Recruiting Industry
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevaci…
Sponsor: Amgen
NCT ID: NCT06252649
Locations: - Ironwood Cancer and Research Centers Scottsdale — Chandler, Arizona
- Providence Saint Jude Medical Center — Fullerton, California
- City of Hope National Medical Center — Long Beach, California
+ 23 more sites in the U.S.
Phase 3 Recruiting Industry
The main goal of this clinical trial is to learn if the drug eRapa works to slow down the progression of disease in patients diagnosed with Familial Adenomatous Polyposis (FAP). Researchers will compare eRapa to Placebo. The questions to b…
Sponsor: Rapamycin Holdings Inc.
NCT ID: NCT06950385
Locations: - City of Hope — Arcadia, California
- Yale Cancer Center — New Haven, Connecticut
- Georgetown University — Washington D.C., District of Columbia
+ 15 more sites in the U.S.
Phase 3 Recruiting Academic/Other
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
Sponsor: Johns Hopkins University
NCT ID: NCT02000089
Locations: - Yale University — New Haven, Connecticut
- Johns Hopkins Hospital — Baltimore, Maryland
- Dana Farber Cancer Center, Harvard University — Boston, Massachusetts
+ 6 more sites in the U.S.
Phase 3 Recruiting Industry
The performance of SGM-101, an intraoperative imaging agent, will be compared to that of standard "white light" visualization during surgical resections of colorectal cancer.
Sponsor: Surgimab
NCT ID: NCT03659448
Locations: - City of Hope National Medical Center — Duarte, California
- Moores Cancer Center - UCSD Health — La Jolla, California
- Cleveland Clinic Florida — Weston, Florida
+ 3 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This research study is comparing two standard of care treatment options based on blood test results for participants who have metastatic colon cancer. The names of the potential treatments involved in this study are: * Active surveillance …
Sponsor: Massachusetts General Hospital
NCT ID: NCT03803553
Locations: - Massachusetts General Hospital — Boston, Massachusetts
- Memorial Sloan Kettering Cancer Center — New York, New York
- Weill Cornell Medical College — New York, New York
Phase 3 Recruiting Industry
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard…
Sponsor: AbbVie
NCT ID: NCT07525206
Locations: - Astera Cancer Care /ID# 279532 — East Brunswick, New Jersey
- Northwell Health Center for Advanced Medicine. /ID# 279590 — Lake Success, New York
- University Of Washington-Fred Hutchinson Cancer Center - Seattle /ID# 281451 — Seattle, Washington
Phase 2, Phase 3 Recruiting Academic/Other
A randomized study of 131 patients. Patients with a clinical T2-3 N0-1 rectal cancer will be randomized to two arms (arm A: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 …
Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
NCT ID: NCT03051464
Locations: - UT Southwestern Medical Center — Dallas, Texas
Phase 1, Phase 2 Recruiting Industry
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Locations: - Ironwood Cancer and Research Centers — Chandler, Arizona
- Mayo Clinic Hospital — Phoenix, Arizona
- HonorHealth Research Institute — Scottsdale, Arizona
+ 29 more sites in the U.S.